Document is current
Any future updates will be listed below
-
Authors
Li, Yan
Zhang, Hua
Sun, Cong https://orcid.org/0000-0003-1786-7420
Dong, Xiao-Dong
Xie, Chu https://orcid.org/0000-0003-1206-3124
Liu, Yuan-Tao https://orcid.org/0000-0002-5071-9780
Lin, Ruo-Bin https://orcid.org/0009-0002-9789-6159
Kong, Xiang-Wei
Hu, Zhu-Long
Ma, Xiao-Yan https://orcid.org/0000-0003-2141-0538
Dai, Dan-Ling
Zhu, Qian-Ying
Li, Yu-Chun
Li, Ying
Liu, Shang-Xin https://orcid.org/0000-0001-9915-9190
Yuan, Li
Zhou, Peng-Hui https://orcid.org/0000-0003-0519-461X
Gao, Song https://orcid.org/0000-0001-7427-6681
Tang, Ya-Ping
Yang, Jin-Ying
Han, Ping https://orcid.org/0000-0001-6097-7794
McGuire, Andrew T.
Zhao, Bo https://orcid.org/0000-0002-8612-5597
Bei, Jin-Xin https://orcid.org/0000-0003-1333-407X
Robertson, Erle https://orcid.org/0000-0002-6088-2979
Zeng, Yi-Xin https://orcid.org/0000-0002-6515-628X
Zhong, Qian https://orcid.org/0000-0003-1071-6996
Zeng, Mu-Sheng https://orcid.org/0000-0003-3509-5591
- License Information
-
More Information
Article History
Received: 22 November 2020
Accepted: 15 May 2025
First Online: 18 June 2025
Competing interests
: Patent applications related to the R9AP monoclonal antibody 5E9 have been submitted to the China National Intellectual Property Administration (patent application number 2024119195522; M.-S.Z., C.S. and C.X. are named inventors). The other authors declare no competing interests.
